Mvasi biosimilar to Avastin and Kanjinti biosimilar to Herceptin are launched in US

Amgen and Allergan plc announced that Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab), are now available in the United States (U.S.).

Mvasi, the first oncology therapeutic biosimilar approved by the FDA, is approved for the treatment of five types of cancer: in combination with chemotherapy for metastatic colorectal cancer (mCRC); in combination with chemotherapy for non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; in combination with interferon-alfa for metastatic renal cell carcinoma; and in combination with chemotherapy for persistent, recurrent, or metastatic cervical cancer.

Kanjinti is FDA approved for all approved indications of Herceptin: for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

The Wholesale Acquisition Cost (WAC or "list price") of both Mvasi and Kanjinti will be 15% lower than their reference products. Mvasi is being made available at a WAC of $677.40 per 100 mg and $2,709.60 per 400 mg single-dose vial, 15% less than the WAC for Avastin. Kanjinti is being made available at a WAC of $3,697.26 per 420 mg multi-dose vial, 15% below the WAC of Herceptin. At launch, Mvasi is priced 12% below the current Avastin Average Selling Price (ASP) and Kanjinti is priced 13% below the current Herceptin ASP. Both products will be available from both wholesalers and specialty distributors.